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Background. With the 2020 target year for elimination of lymphatic filariasis (LF) approaching, there is an urgent need to assess 
how long mass drug administration (MDA) programs with annual ivermectin + albendazole (IA) or diethylcarbamazine + albenda-
zole (DA) would still have to be continued, and how elimination can be accelerated. We addressed this using mathematical modeling.
Methods. We used 3 structurally different mathematical models for LF transmission (EPIFIL, LYMFASIM, TRANSFIL) to sim-
ulate trends in microfilariae (mf) prevalence for a range of endemic settings, both for the current annual MDA strategy and alterna-
tive strategies, assessing the required duration to bring mf prevalence below the critical threshold of 1%.
Results. Three annual MDA rounds with IA or DA and good coverage (≥65%) are sufficient to reach the threshold in settings 
that are currently at mf prevalence <4%, but the required duration increases with increasing mf prevalence. Switching to biannual 
MDA or employing triple-drug therapy (ivermectin, diethylcarbamazine, and albendazole [IDA]) could reduce program duration by 
about one-third. Optimization of coverage reduces the time to elimination and is particularly important for settings with a history 
of poorly implemented MDA (low coverage, high systematic noncompliance).
Conclusions. Modeling suggests that, in several settings, current annual MDA strategies will be insufficient to achieve the 2020 
LF elimination targets, and programs could consider policy adjustment to accelerate, guided by recent monitoring and evaluation 
data. Biannual treatment and IDA hold promise in reducing program duration, provided that coverage is good, but their efficacy 
remains to be confirmed by more extensive field studies.
Keywords. lymphatic filariasis; elimination; mass drug administration; mathematical modeling.
Lymphatic filariasis (LF) is a mosquito-borne parasitic disease 
endemic in 72 countries [1], affecting millions of people, with 
many of them suffering from hydrocele or lymphedema (ele-
phantiasis), associated mental health problems, social margin-
alization, or reduced productivity [2–4]. The Global Programme 
to Eliminate Lymphatic Filariasis (GPELF) was set up in 2000, 
aiming to eliminate LF worldwide as a public health problem 
by 2020. Two pillars of the program are to (1) interrupt trans-
mission by implementing at least 5 rounds of annual mass drug 
administration (MDA) of a 2-drug combination (ivermectin + 
albendazole [IA] in onchocerciasis-endemic areas, and diethyl-
carbamazine + albendazole [DA] elsewhere), and (2) reduce the 
suffering of patients through proper morbidity management 
[1]. In this article, “elimination” refers to the achievement of 
this first objective via the reduction of infection to below a 1% 
microfilariae (mf) prevalence threshold.
Great progress has been made toward the 2020 elimination 
goals. More than 820 million people have been treated at least 
once [1]. According to the Global Burden of Disease study, the 
number of infected cases declined from 53 million in 2000 to 29 
million in 2016. In the same period, the burden of disease in dis-
ability-adjusted life-years declined from 1.9 million to 1.2 million 
[5]. Eighteen endemic countries have completed their MDA pro-
grams and are under post-MDA surveillance, and 25 countries 
have successfully implemented MDA in all endemic districts 
and may be considered on track to elimination. In some treated 
areas, however, the decline in mf prevalence has been slower 
than expected, possibly due to low coverage, mosquito vector 
characteristics, high transmission intensity, or differences in effi-
cacy between treatment regimens [6]. Furthermore, another 20 
countries are treating only part of their endemic districts, and 9 
countries have not yet started [1]. The untreated areas include 
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Loa loa–coendemic areas in central Africa, where DA and IA 
are contraindicated because of safety concerns. The provisional 
strategy for these areas is to implement twice-yearly MDA with 
albendazole alone, in combination with vector control [7, 8].
Program acceleration is required to maximize the number of 
countries achieving the 2020 elimination targets and minimize 
the additional efforts required after this year. Keeping the pro-
grams short is also important to sustain the global momentum 
for LF elimination among all stakeholders. Therefore, the World 
Health Organization recently published new guidelines on alter-
native MDA regimens to eliminate LF [9]. Alternative strategies 
considered in this report include increasing the frequency of 
treatment from annual to biannual (every 6 months), using the 
supposedly more efficacious triple-drug treatment combination 
of ivermectin, diethylcarbamazine, and albendazole (IDA) [10], 
and biannual MDA with albendazole alone for loiasis-coen-
demic areas, where neither diethylcarbamazine nor ivermectin 
can be used in view of high risk of side reactions. Unfortunately, 
empirical evidence on the comparative effectiveness of current 
vs alternative proposed strategies is still limited [9].
Mathematical models provide powerful tools to compare 
the impact of alternative interventions for infectious diseases 
when empirical evidence is insufficient [11]. Three mathemat-
ical models for LF are actively being used to support policy 
making for LF elimination programs, named EPIFIL [12, 13], 
LYMFASIM [14–16], and TRANSFIL [17, 18]. While there are 
many similarities between the models, there are also important 
differences in model structure, parameter quantification, and 
application methods, which can result in different predictions. 
Recognizing the need for robust policy advice, the 3 respective 
modeling groups are now collaborating in multimodel compari-
son studies and providing combined model predictions. They 
showed that all 3 models can reproduce observed trends in mf 
prevalence during MDA or integrated vector management [19] 
and that estimates of the required duration of MDA to reduce 
mf prevalence below the 1% critical threshold are of the same 
order of magnitude, although differences remain [20].
In the current article, we use these 3 models to estimate how long 
MDA programs still have to be continued with current strategies, 
and to what extent the required MDA duration can be reduced 
by optimizing coverage, increasing the frequency of treatment to 
biannual administration, or using IDA. We do this by simulating 
scenarios for 3 geographic regions and a wide range of baseline 
endemicity levels, both for treatment-naive areas and for areas with 
a history of MDA where strategy adjustment is considered.
METHODS
Simulated Settings and Scenarios
We performed simulations for bancroftian filariasis endemic 
settings in India, Africa, and Papua New Guinea (PNG), 
accounting for regional differences in human demography, 
local vector species (Culex quinquefasciatus in India, Anopheles 
species in Africa, and PNG), the possible range of precontrol 
mf prevalence levels (1%–15% in India, 1%–40% in Africa, 
1%–70% in PNG), and the regional standard treatment regi-
mens (DA in India and PNG; DA, IA, or albendazole in Africa, 
depending on coendemicity of onchocerciasis and loiasis).
Settings were further defined by the local history of MDA 
until present (t = 0), considering 4 alternatives: treatment-naive 
(TN) settings, which have not received any previous treatment 
and t = 0 is the precontrol situation; recently started (RS) settings, 
which have had 2 rounds of MDA before t = 0 with 65% cover-
age per round, and t = –2 is the precontrol situation; failure type 
1 (F1) settings that have had 10 annual rounds of MDA before 
t = 0, but with low coverage (50%); and failure type 2 (F2) set-
tings that have had 10 annual rounds of MDA, but with very low 
coverage (30%). For F1 and F2, t = –10 is the precontrol situation. 
Historical MDA rounds always involved the regional standard 
treatment regimens as given above. Coverage is here defined as 
the proportion treated per round out of the whole population. 
Poor coverage in F1 and F2 settings is assumed to be associated 
with systematic noncompliance, meaning that some people never 
take treatment, although this is only captured by LYMFASIM and 
TRANSFIL (see Supplementary Data 1–3 for details).
For each combination of region and history of control, we 
simulated trends in mf prevalence under alternative future 
treatment scenarios. Reference scenario is the currently rec-
ommended strategy of annual MDA with the regional standard 
regimen (DA, IA) with 65% coverage per round. Alternative 
scenarios include an increase in coverage (from 65% to 80%), 
an increase in frequency (from annual to biannual), or a switch 
to IDA treatment. For Loa loa–coendemic areas, we considered 
twice-yearly albendazole with 65% or 80% coverage. For F1 and 
F2 settings, we also examined what would happen if annual 
MDA were continued with the same low coverage.
Models and Assumptions on Key Parameters
All 3 models simulate LF transmission in a closed, age-struc-
tured human population, tracking trends in various infec-
tion indicators over time. They capture the basic processes 
determining transmission, including characteristics of the 
parasite life cycle, age-specific rates of exposure to vectors, 
and vector biting rate and efficiency. EPIFIL and LYMFASIM 
also consider acquisition of immunity to infections. The 
models mimic the impact of MDA, accounting for treatment 
effects on different parasite stages, achieved coverage, and 
(for LYMFASIM and TRANSFIL) underlying compliance 
patterns (who is being treated in each round and who is not). 
They differ in the details of the implementation methods and 
parameter quantification. EPIFIL is a deterministic popu-
lation-based model, while LYMFASIM and TRANSFIL are 
stochastic individual-based. LYMFASIM also models worms 
individually, while TRANSFIL models them at a population 
level inside the host.
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Here, all 3 models used the same assumptions on treatment 
efficacy, with treatment regimens differing in the proportion 
of adult worms and mf killed, and a temporary or permanent 
reduction in mf productivity by surviving adult worms, as indi-
cated in Table 1.
Simulation Runs and Analysis
We generated 10 000 simulations for each setting (defined by 
region, history of control) and future treatment scenario, var-
ying a selection of parameters such that resulting prevalence 
levels at t  =  0 capture the entire region-specific precontrol 
prevalence range for treatment-naive settings. LYMFASIM and 
TRANSFIL varied specific parameters concerning local trans-
mission conditions (mean and variation in vector density or 
biting rate, external force of infection) with additional variation 
resulting from intrinsic stochasticity, while all other parameters 
were treated as fixed. EPIFIL varied 20 parameters, capturing 
not only variation in local transmission conditions and but 
also uncertainty in other factors (Supplementary Data 1–3). 
The corresponding prevalence levels at t = 0 are lower for RS, 
F1, and F2 settings, depending on the predicted impact of past 
interventions. LYMFASIM has not been calibrated for PNG and 
was not run for that region.
Our simulations start at t = –10 (ie, 10 years before the pres-
ent) and end at t = 20 (ie, 20 years into the future). Future alter-
native treatment strategies start with their first treatment at 
t = 0 and are continued 20 years thereafter with treatment every 
6 or 12 months. Historical treatments took place from t = –2 
(RS) or t = –10 (F1, F2) onward, with the last historic treatment 
at t = –1. Per run, we stored the mf prevalence in the total pop-
ulation at yearly intervals, with the mf prevalence measured just 
before a treatment. Dynamic changes in between yearly meas-
urements are not analyzed.
Per run we documented the year in which the mf preva-
lence first fell below 1%, assuming t = 21 for runs not achieving 
this target. Per setting and treatment scenario, we then calcu-
lated the moving average to show how this required treatment 
duration varied with the prevalence at t  =  0 (window bin-
size = 501). Prediction intervals were calculated by bootstrap-
ping; 10 000 samples were taken out of the original simulation 
runs with replacement, for each sample the 90% interval of time 
to achieving the threshold was calculated, and finally the 95% 
range over all the ranges per sample was determined. We iden-
tified strategies that lead to elimination within 3 years, which 
would be sufficient to reach the 2020 target, if adjusted strate-
gies are implemented from 2018 onward.
Code Availability
The code for the version of LYMFASIM used in this paper is 
provided in Supplementary Data 4. The code of TRANSFIL and 
EPIFIL can be accessed via github [21, 22].
RESULTS
Figure 1 shows the MDA duration required to bring mf prev-
alence below 1% for different strategies in treatment-naive 
settings, comparing the current strategy of annual MDA with 
standard 2-drug combination and 65% coverage with alter-
native strategies, that differ from the current strategy in one 
aspect—namely, the employed treatment regimen (switch 
to the triple-drug regimen), frequency of treatment (switch 
to biannual MDA), or the treatment coverage (increased to 
80%). Corresponding trends in mf prevalence are presented 
in Supplementary Data 5, which also shows what happens if 
some of the above alternative strategies are combined (eg, tri-
ple drug or biannual MDA with 80% coverage). The required 
duration is shortest for the low-prevalence Indian setting, but 
still exceeds 3 years if MDA continues annually with DA at 65% 
coverage, meaning that elimination would not be achieved by 
2020. Increasing the coverage to 80% results in some acceler-
ation, but a stronger time reduction is obtained with annual 
IDA. Biannual treatment results in the strongest reduction, but 
requires more treatment rounds than the other acceleration sce-
narios. Similar patterns are seen in the other regions. While the 
3 models yield very similar results for India, they are less con-
sistent in the other regions (up to 3 years apart), with EPIFIL’s 
estimates usually being the shortest (Figure 1).
The time needed to achieve the 1% threshold in treat-
ment-naive settings depends strongly on the mf prevalence 
at t = 0 (Figure 2). For mf prevalence levels <3%–4%, 3 years 
of annual MDA with currently recommended 2-drug combi-
nations is sufficient to reach the 1% threshold, but alternative 
strategies are required for higher prevalences. Switching from 
DA to IDA enables settings with current mf prevalence up to 
10%–15% to achieve the goal in 3 years. In African areas with 
IA treatment, switching to biannual treatment means that areas 
with prevalence as high as 20% could achieve this time-bound 
goal, at least according to EPIFIL. The other 2 models predict 
that only areas with prevalence <10% would achieve the targets 
within 3 years.
Interestingly, the remaining required MDA duration depends 
only on current mf prevalence, treatment strategy, and achieved 
coverage, but not on the history of control, provided that prob-
lems with low coverage and systematic noncompliance are 
Table 1. Treatment Efficacy Assumptions Adopted
Treatment Regimen
Proportion of 
Adult Worms 
Killed, %
Duration of 
Sterilization, mo
Proportion of 
Microfilariae 
Killed, %
DEC + ALB 55% 6 95
IVER + DEC + ALB 
(optimistic)a
55% Permanent 100
IVER + ALB 35% 9 99
ALB 35% 0 0
Abbreviations: ALB, albendazole; DEC, diethylcarbamazine; IVER, ivermectin; mo, month.
aTriple-drug regimen, for which we adopted optimistic treatment efficacy assumptions.
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corrected. This is illustrated for annual MDA in African settings 
with different histories of control in Figure  3 (upper panels). 
Region also does not play a role for a given treatment regimen 
(Supplementary Data 5). The bottom panels of Figure 3 further 
illustrate the importance of achieved coverage/compliance for 
treatment-naive African settings treating annually with DA. The 
required duration can be reduced by 1–3  years (depending on 
baseline mf prevalence and model) if coverage is increased from 
an acceptable 65% to 80%, whereas a low coverage in combin-
ation with a high proportion of people never participating in 
MDA makes it virtually impossible to reach the threshold within 
a reasonable time frame.
CONCLUSIONS
The importance of good coverage, with minimal systematic 
noncompliance, for the success of elimination campaigns is 
widely recognized [23–25]. Determinants of poor coverage are 
being studied, and methods for improvement are being devel-
oped [26–29]. While a coverage of 65% may be considered 
acceptable, increasing it to 80% leaves less room for systematic 
noncompliance and helps to shorten elimination programs. The 
benefits are even larger for settings with lower coverage or more 
systematic noncompliance than assumed here.
MDA durations can also be shortened by increasing the 
frequency of treatment, because a larger number of people 
will be treated at least once per year, and those treated twice 
are expected to experience a greater reduction in their worm 
and mf loads. Unfortunately, empirical evidence to corroborate 
the model-predicted benefit of biannual over annual MDA is 
scarce. Clinical trials with IA confirm that the overall reduc-
tion in mf count is larger in individuals treated twice, although 
there was no evidence of a larger adulticidal effect [30, 31], and 
one community intervention study reported a faster decline in 
mf prevalence during biannual MDA with diethylcarbamazine 
vs annual MDA [32]. Additional evidence is anticipated from 
ongoing community intervention trials. However, outcomes of 
such trials are notoriously difficult to interpret due to variation 
between treatment arms in baseline endemicity, between-sur-
vey variation in population samples, absence of individual-level 
longitudinal data, and uncertainty about achieved coverage pat-
terns. The impact of increasing treatment frequency is highly 
dependent on the assumption that good coverage is maintained; 
the benefits would diminish if coverage drops due to implemen-
tation challenges.
Switching to the triple-drug regimen IDA is predicted to 
reduce the remaining duration of MDA programs by about 
Figure 1. Required duration of mass drug administration (MDA) to bring microfilariae (mf) prevalence below the 1% critical threshold in treatment-naive settings, com-
paring the result from the 3 different models. The setting under consideration is specified in the caption of each subpanel, indicating the geographical region, recommended 
standard treatment regimen, and the precontrol mf prevalence considered. The current strategy (annual MDA with the recommended standard regimen at 65% coverage) is 
compared with alternative strategies differing in one aspect, including a switch to triple-drug regimen (ivermectin + diethylcarbamazine + albendazole; annual, 65% cover-
age), switch to biannual MDA (standard regimen, 65% coverage), or increased coverage of 80% (annual, standard regimen). Vertical line at t = 3 indicates the target year 
of elimination (ie, 2020, 3 years from the time of writing this paper). Error bars indicate the 90% prediction interval as calculated through bootstrapping. aSimulations for 
triple-drug scenarios were done with optimistic efficacy assumptions, as provided in Table 1. bImpact of increased coverage is shown for annual MDA, except for the “Africa 
ALB only” region, where it is shown for biannual MDA. Abbreviations: ALB, albendazole; cov., coverage; DEC, diethylcarbamazine; IVER, ivermectin; mf, microfilariae; PNG, 
Papua New Guinea; prev., prevalence.
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Figure 2. Average time needed to reach the 1% target of microfilariae (mf) prevalence in treatment-naive settings, in relation to the mf prevalence at t = 0. Each subplot 
represents a particular region as specified in its caption. Within each panel, results are shown for the current strategy of annual mass drug administration (MDA) with either 
ivermectin + albendazole (IA) or diethylcarbamazine + albendazole in comparison to ivermectin + diethylcarbamazine + albendazole (IDA; for India, Papua New Guinea, and 
the African DA regions) or biannual MDA (African IA region, where IDA is not recommended because of safety concerns). For Loa loa–coendemic areas, biannual MDA with 
albendazole alone is the recommended strategies and no alternative is shown. Horizontal line at t = 3 indicates 2020. Abbreviations: ALB, albendazole; DEC, diethylcarba-
mazine; IVER, ivermectin; PNG, Papua New Guinea.
Figure 3. The association between the average time needed to reach the 1% target of microfilariae (mf) prevalence and mf prevalence at t = 0, for programs based on 
annual distribution of diethylcarbamazine + albendazole in the African region. The upper panels show how the history of control affects this association, assuming that 
coverage is 65% from t = 0 onward, independent of the history of control. The lower panels show how the program duration in treatment-naive settings depends on achieved 
coverage and compliance patterns from t = 0 onward. Horizontal line at t = 3 indicates 2020. Note that the black lines in the upper and lower panels per model are the same. 
Abbreviations: cov., coverage; syst., systematic.
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a third. The superior efficacy of IDA over DA was shown in 
a small clinical trial from PNG [33] and confirmed in other, 
yet unpublished, trials [10]. The difference was attributed to a 
stronger adulticidal or more sustained embryostatic efficacy 
and the drug is now seen as a potential game changer for LF 
elimination [10, 33]. Accordingly, we assumed optimistically 
that IDA kills about the same proportion of adult worms and mf 
as DA, and also permanently sterilizes any surviving adults. Yet, 
the evidence base underlying these assumptions is still limited. 
If the sterilizing effect is lower or less sustained than assumed, 
the impact of annual IDA approximates that of DA, with no 
difference at all in the worst case [20]. More field studies are 
needed to better understand the efficacy of IDA.
When choosing between alternative treatment strategies, 
policy makers should also consider the costs, feasibility, and 
acceptability. While biannual MDA leads to the strongest pre-
dicted reduction in program duration, its implementation 
requires additional financial and human resources in already 
overburdened health systems [34, 35]. This may be less of a 
problem for strategies involving improved coverage or better 
drugs. Therefore, annual IDA treatment may be more attractive 
to many stakeholders, but its impact may decline with a lower 
population acceptation of having to swallow multiple tablets. 
Furthermore, diethylcarbamazine is contraindicated for MDA 
in onchocerciasis-coendemic areas, making IDA not an option 
for now. Yet, it could perhaps be used after a pretreatment with 
ivermectin, as suggested elsewhere [10].
Our study has some limitations. First, we have estimated 
the required program duration for bringing the mf prevalence 
below a 1% threshold, without assessing whether this eventu-
ally leads to true extinction of the parasite in the population. 
With a higher threshold of 2%, the required duration would 
decrease with about 1 year (EPIFIL) or 2 years (LYMFASIM and 
TRANSFIL), while similar increases in duration are expected 
if a 0.5% threshold is used. Previous modeling suggests that 
the threshold depends on local transmission conditions and 
declines with increasing transmission intensity [36–38]. The 
probability of true elimination after reaching a predefined 
threshold could be further investigated using the individu-
al-based models, but even then it will be challenging to prop-
erly account for factors such as reintroduction of infection from 
neighboring areas. Also, some countries use antigen tests (eg, 
the filarial test strip) for surveys in sentinel and spot check sites, 
using an antigenemia prevalence <2% as target. The latter tar-
get is not necessarily equivalent to the 1% target mf prevalence, 
which could lead to different program durations than presented 
in this article. Second, our simulations are for single populations, 
whereas actual elimination programs typically take districts as 
their implementation unit. Within-district variation in baseline 
endemicity and achieved coverage and compliance patterns will 
lead to variation in the required MDA duration. Unfortunately, 
coverage data are often of poor quality [39]. Even if the mean 
reported coverage in a district is acceptable, there can still be 
sites with poor coverage, which is particularly problematic if it 
occurs in high-transmission foci. Third, we focused on improv-
ing MDA strategies and have not assessed the benefits of other 
strategies, such as supplemental vector control or diethylcarba-
mazine-fortified salt distribution. The latter in particular could 
be extremely effective, but it requires a very different implemen-
tation strategy than the current tablet-based programs [40, 41]. 
We showed previously that the impact of complementary vector 
control on program duration is limited [20].
All model predictions are subject to uncertainty. The error 
bars in Figure 1 capture uncertainty about the local transmis-
sion conditions underlying a certain prevalence and chance 
effects in small populations for LYMFASIM and TRANSFIL, 
and uncertainty in a larger set of parameters without chance 
effects for EPIFIL. By contrasting 3 models, we also capture 
variation resulting from structural model uncertainty. Usually 
EPIFIL is somewhat more optimistic than the other models, 
which is due to its assumption that treatments are randomly 
distributed over the population without systematic noncompli-
ance. Between-model differences in assumptions on the para-
site life cycle, density dependence in transmission processes, or 
population structure are probably less influential to treatment 
duration estimates, given the assumed high efficacy of available 
treatment regimens and corresponding limited bounce-back 
of LF infection between annual MDA rounds. However, they 
can give rise to important differences in estimated elimination 
thresholds, as shown elsewhere for onchocerciasis [42].
In conclusion, the remaining required duration of MDA for 
reducing mf prevalence below the critical 1% threshold greatly 
depends on the current mf prevalence and chosen strategy (treat-
ment regimen, frequency, achieved coverage, and compliance 
pattern), but not geographic region and past MDA history, pro-
vided that any problems with poor coverage are solved. The ambi-
tious 2020 target for LF elimination is unlikely to be met where 
mf prevalence is still well above 3%–4%. MDA programs can be 
accelerated by optimizing coverage, switching to biannual MDA, 
or switching to the supposedly more efficacious triple-drug regi-
men IDA. Yet even then the 2020 target likely remains out of reach 
for settings with prevalence >10%–15%, although the elimination 
threshold could be achieved a few years down the line.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
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